Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11188353 | 0.80 | ELANE (0.55) | ELANEFNTAFNTBPGGT1BHPGD | |
| SCHEMBL11188356 | 0.80 | ELANE (0.55) | ELANEFNTAFNTBPGGT1BHPGD | |
| SCHEMBL7347925 | 0.78 | DAO (0.47) | ELANEHPGDMAPTADAM17KMT2A | |
| Hydrochloric Acid SCHEMBL7353048 | 0.76 | ELANE (0.46) | ELANEHPGDMAPTADAM17KMT2A | |
| SCHEMBL6414266 | 0.73 | MME (0.43) | MMECTSKACECPA1ACE2 | |
| SCHEMBL11189595 | 0.73 | ELANE (0.45) | ELANEFNTAFNTBHPGDMAPT | |
| SCHEMBL11189604 | 0.72 | ELANE (0.51) | ELANEHPGDMAPTADAM17KMT2A | |
| SCHEMBL11187178 | 0.72 | ELANE (0.51) | ELANEHPGDMAPTADAM17KMT2A | |
| SCHEMBL11190192 | 0.72 | ELANE (0.51) | ELANEHPGDMAPTADAM17KMT2A | |
| SCHEMBL11189623 | 0.72 | ELANE (0.51) | ELANEHPGDMAPTADAM17KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0557303-B1 | N- (2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RES SRL (IT) | 1994-09-14 | — | — | EP | claimed |
| WO-1992008713-A1 | N-[(2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RESEARCH S.R.L. (IT) | 1992-05-29 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0557303-B1 | N- (2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RES SRL (IT) | 1994-09-14 | — | — | EP | disclosed |
| EP-0557303-B1 | N- (2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RES SRL (IT) | 1994-09-14 | — | — | EP | disclosed |
| EP-0557303-A1 | N- (2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. | MEDEA RES SRL (IT) | 1993-09-01 | — | — | EP | disclosed |
| EP-0557303-A1 | N- (2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. | MEDEA RES SRL (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1992008713-A1 | N-[(2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RESEARCH S.R.L. (IT) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008713-A1 | N-[(2-THENOYLMERCAPTO-3-METHYL)-BUTANOYL]-HOMOCYSTEINE THIOLACTONE, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RESEARCH S.R.L. (IT) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ELANE 554/4885FNTA 322/4885FNTB 935/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ELANE 554/4885FNTA 322/4885FNTB 935/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ELANE 554/4885FNTA 322/4885FNTB 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.